Clinical target promiscuity: lessons from ras molecular trials.
about
Found in translation: Integrating laboratory and clinical oncology researchClinical relevance of KRAS in human cancers.A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Kinase-independent role for CRAF-driving tumour radioresistance via CHK2Molecular targets for tumor radiosensitization.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
P2860
Clinical target promiscuity: lessons from ras molecular trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical target promiscuity: lessons from ras molecular trials.
@en
Clinical target promiscuity: lessons from ras molecular trials.
@nl
type
label
Clinical target promiscuity: lessons from ras molecular trials.
@en
Clinical target promiscuity: lessons from ras molecular trials.
@nl
prefLabel
Clinical target promiscuity: lessons from ras molecular trials.
@en
Clinical target promiscuity: lessons from ras molecular trials.
@nl
P2093
P2860
P1476
Clinical target promiscuity: lessons from ras molecular trials.
@en
P2093
Keith A Cengel
Ramesh Rengan
Stephen M Hahn
P2860
P2888
P304
P356
10.1007/S10555-008-9133-Z
P577
2008-09-01T00:00:00Z